IRTC — iRhythm Technologies, Inc.

Summary of iRhythm Holdings Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $199.4 million, up 25.7% year-over-year, exceeding expectations.
• Adjusted EBITDA: $14.1 million (7.1% of revenue), an improvement of 880 basis points year-over-year.
• Gross Margin: 70.9%, an increase of 210 basis points year-over-year.
• Net Loss: GAAP net loss of $13.9 million ($0.43 per diluted share), improved from a loss of $30.7 million in Q1 2025.
• Free Cash Flow: Negative $33 million, typical seasonal pattern.
• Cash Position: $549.6 million in cash, cash equivalents, and marketable securities.

2. Strategic Updates and Business Highlights

• Growth Drivers: Strong performance across Zio Monitor and Zio AT, with significant contributions from cardiology, primary care, innovative channels, and international markets.
• Market Expansion: iRhythm is focusing on expanding the long-term continuous monitoring market, emphasizing the limitations of short-duration monitoring.
• EHR Integration: 53% of volume now flows through EHR-integrated accounts, enhancing workflow efficiency.
• International Success: Best quarter in the U.K. and positive reimbursement updates in Japan.
• AI Initiatives: Progress in AI capabilities, including a next-generation algorithm expected to reduce clinical technician review time significantly.

3. Forward Guidance and Outlook

• Revenue Guidance: Raised full-year 2026 revenue guidance to $875 million - $885 million, reflecting 17% to 18% year-over-year growth.
• Adjusted EBITDA Margin Guidance: Increased to 12% - 13% for the full year.
• Q2 Revenue Expectation: Anticipated revenue of $218 million - $220 million.
• Long-Term Goals: Continued focus on expanding market share, particularly in primary care and innovative channels.

4. Bad News, Challenges, or Points of Concern

• Regulatory Issues: Ongoing FDA warning letter and the need for continued compliance and remediation efforts.
• DOJ Investigation: Active investigation related to the AT product line, with no new requests for information but uncertainty remains.
• Market Competition: Concerns about potential competition from AI-driven solutions outside traditional medtech, although management feels confident in their comprehensive service offering.
• Economic Pressures: Mention of geopolitical factors and their potential impact on gross margins, though currently not expected to be material.

5. Notable Q&A Insights

• Guidance Adjustments: Management indicated the revenue guidance reflects a conservative approach, considering potential future upside but acknowledging tougher year-over-year comparisons.
• AI Competition: Management emphasized the defensibility of their business model, highlighting their end-to-end service and extensive clinical data as competitive advantages.
• Sleep Market Potential: Management expressed optimism about the sleep market, indicating ongoing pilots and a strategic approach to streamline sleep diagnostics.
• Regulatory Developments: Discussion around the proposed local coverage determination (LCD) and its implications for monitoring categories, with management actively engaging with MACs for clarification.
• Electrophysiology (EP) Market: Management noted no current signs of slowdown in EP, emphasizing the importance of long-duration monitoring post-ablation.

Overall, iRhythm reported strong financial results and positive strategic developments while navigating regulatory challenges and competitive pressures. The company remains focused on leveraging its platform for sustained growth and market expansion.